Looking at the pipelines of recent biotech IPOs is a great way to get a snapshot of new technologies and approaches to drug discovery or to see what’s coming in smaller indications. Complementing our recent highlight of large molecule-focused companies, …
Browsing through the pipelines of recent biotech IPOs is great way to catch up on emerging targets, novel drug modalities, and science at the edge of development. Unlike conferences and publications which tend to be a lagging indicator of what’s …
June’s edition of Small Molecules of the Month features a natural product-derived RNA splicing modulator, a mTORC1-selective “bi-steric” inhibitor, numerous low-dose clinical candidates and several unusual chemical motfs (e.g. pyridine N-oxide, sulfinylamine, boronic acid). Links to articles, PDF download, and …
By Christian Gampe While biologic drugs currently dominate in immunology by sales, small molecule immunomodulators (SMIMs) are making a comeback fueled by better understanding of intracellular signaling pathways and new hit finding technologies. SMIMs can be grouped into two categories: …
Which drug hunters are making the greatest scientific contributions to drug discovery R&D? We have some drug hunters in mind…
In May’s edition of Small Molecules of the Month, we have several fascinating molecules including a mutant PI3Kα degrader in Ph. III (GDC-0077, inavolisib), a wild-type CFTR potentiator for COPD, and a Ph. III chemotherapeutic derived from an aerospace compound. …